Re-engineering Ovarian Response Through
Precision Androgen Priming
A formulation-driven approach to improving outcomes in poor responders undergoing assisted reproductive technologies.
Transforming a biologically validated concept into a controlled, predictable, and clinically viable therapy.
A widely used concept — with no approved solution
A validated biological intervention, constrained not by the pharmacology but by the absence of purpose-built delivery.
In assisted reproductive technologies (ART), a subset of patients — commonly classified as poor responders — fail to produce adequate oocytes despite high-dose stimulation. Short-term androgen pre-treatment has shown strong biological rationale and growing clinical use.
Yet the field is caught in a frustrating paradox: the science is well-established, but a fit-for-purpose solution does not exist. Three critical gaps define the current landscape:
There is no approved formulation for women — the pharmacological need remains clinically unaddressed.
Current practice relies on off-label adaptation of male products — a pragmatic workaround, not a solution.
Delivery remains imprecise, inconsistent, and poorly controlled — undermining the very rationale for treatment.
"The science exists. The delivery does not."
Priming ovarian biology before stimulation begins
Androgens play a critical role in early follicular development — acting upstream to prepare the ovary for a more efficient stimulation response.
Short-term androgen pre-treatment acts at the biological level to fundamentally alter the ovarian environment before controlled stimulation commences. The mechanisms are well-characterised and biologically compelling.
Promotes recruitment of resting follicles from the primordial pool
Enhances transition into the growing follicle pool, expanding the available cohort
Upregulates FSH receptor expression in granulosa cells — increasing sensitivity to stimulation
When controlled ovarian stimulation begins, the ovary is pre-conditioned to respond more effectively. The anticipated outcomes reflect this biological preparation:
Androgen priming does not replace stimulation — it transforms the environment in which stimulation occurs, shifting the biology in favour of response before the cycle begins.
Imprecision at the level of delivery
Three interrelated delivery failures limit the therapeutic potential of androgen priming in clinical practice.
Today's clinical practice is constrained not by the biology — but by non-optimised formulations. The use of male-oriented gel products, applied in fractional doses, introduces variability that makes a precision intervention clinically unreliable.
"The challenge is not the pharmacology — it is precision delivery engineering."
From off-label workaround to engineered therapy
Androgen priming is approached as a controlled, short-duration intervention with specific engineering requirements — not as a reformulation exercise.
The starting premise is simple: if the biology is sound but the delivery fails, the solution is a purpose-built delivery architecture. This means approaching androgen priming as what it actually is — a precision micro-dosing challenge with stringent pharmacokinetic requirements.
Three engineering requirements define what an effective platform must achieve:
Micro-dose precision — accurate delivery at microgram-level resolution, without reliance on approximate patient-applied fractions
Predictable pharmacokinetics — consistent absorption profiles that translate reliably across patients and cycles
High patient compliance — a formulation and device format that patients can use correctly throughout the priming window
Precision transdermal delivery systems — engineering controlled, reproducible androgen exposure for women undergoing ART.
The focus is not on reformulating an existing product — it is on building a precision micro-dosing architecture from the ground up, designed specifically for the physiological requirements of women undergoing ART.
Engineering controlled delivery systems
Three complementary delivery engineering strategies — each targeting a distinct failure mode of current clinical practice.
Nano-Enabled Transdermal Systems
- Encapsulation of androgen in nano-emulsion and lipid systems
- Controlled droplet size for predictable dermal permeation
- Reduced reliance on harsh penetration enhancers
Metered-Dose Delivery Devices
- Airtight, calibrated dispensing systems for precise actuation
- Microgram-level dosing accuracy per application
- Eliminates patient-dependent dosing variability
Advanced Transdermal Architectures
- Polymeric delivery systems for sustained, controlled release
- Alternative permeation pathways under active investigation
- Controlled-release skin-interface systems
Variability → precision
Converting a variable, off-label intervention into a clinically reliable, purpose-engineered therapeutic tool.
"Converting a variable intervention into a clinically reliable tool."
Predicting transdermal behaviour before formulation
Skin delivery of lipophilic molecules is governed by physical chemistry principles that are computationally tractable — precisely where SynapTx provides decisive advantage.
Transdermal delivery of lipophilic molecules such as testosterone is governed by well-defined physical chemistry principles — partition coefficients, diffusion kinetics, and excipient–membrane interactions. These are computationally tractable, and SynapTx is built to model them with precision.
Governing parameters SynapTx models
Partition coefficients across skin layers — predicting drug distribution profiles
Flux through the stratum corneum — modelling rate-limiting permeation steps
How formulation components alter and modulate permeation behaviour
This enables simulation of dermal permeation profiles in silico, prediction of steady-state flux, and optimisation of formulation matrices — all before bench work begins. The result: reduced experimental iterations, lower resource expenditure, and compressed development timelines.
A short-duration, high-impact therapeutic window
Unlike chronic hormone therapies, the androgen priming window offers a uniquely favourable risk–benefit profile with strong regulatory and commercial characteristics.
Time-Limited Intervention
A 30–60 day treatment window — not a chronic therapy, significantly reducing cumulative risk exposure.
Defined Clinical Window
Targets a specific biological phase prior to stimulation with clear, measurable clinical endpoints.
Favourable Risk–Benefit
Short treatment duration limits cumulative exposure whilst delivering measurable reproductive benefit.
A well-defined regulatory acceptance pathway, potential for rapid clinical translation, and strong market differentiation — in a segment where no purpose-built product currently exists.
Precision. Control. Translation.
Three principles that define our approach to every programme — from androgen priming to broader formulation-led development challenges.
Principle 01
Translational Engineering
Turning known biology into clinically viable therapies by solving the delivery problem — not re-discovering the pharmacology.
Principle 02
Formulation-Led Innovation
Addressing delivery challenges as the primary constraint on therapeutic translation, rather than focusing on novel molecule discovery.
Principle 03
Predictive Development
Using computational models through SynapTx to guide formulation decisions, reducing empirical cycles and compressing timelines.
Co-develop the next generation of ART optimisation strategies
Actively seeking partners who share our commitment to translational precision in women's reproductive health — from early concept through to clinical application.
We collaborate across the full development spectrum, from molecules and biological pathways through to advanced delivery technologies and clinical translation. Current partner interests include:
Fertility clinics and reproductive medicine centres
Pharmaceutical companies with women's health portfolios
Women's health innovators and research organisations
Academic and clinical research groups in reproductive biology
Partner With Us to Develop Precision ART Therapies
We are actively seeking pharmaceutical partners, fertility clinics, and research collaborators to advance this platform from formulation concept to clinical reality. If you are working at the intersection of women's health, reproductive medicine, and delivery science — we would welcome a conversation.